102 research outputs found

    Machinery Investment in Illinois: A Study Examining Existing Investment Motivations

    Get PDF
    In this study, we attempt to prove some previously held ideas of machinery investment decisions using farm level data from Illinois. Investment decisions are analyzed taking into consideration past investment decisions in the county and on the individual farm. The results show there is a correlation between county level purchases and individual farm purchases and investment levels decrease the following year after an initial investment. These results display how non-traditional drivers for investment also play an important role in the investment decision.machinery, investment, keeping up with the Jones', treadmill theory, Farm Management,

    Glycosaminoglycan and Proteoglycan Biotherapeutics in Articular Cartilage Protection and Repair Strategies: Novel Approaches to Visco?supplementation in Orthobiologics

    Get PDF
    The aim of this study is to review developments in glycosaminoglycan and proteoglycan research relevant to cartilage repair biology and in particular the treatment of osteoarthritis (OA). Glycosaminoglycans decorate a diverse range of extracellular matrix and cell associated proteoglycans conveying structural organization and physico‐chemical properties to tissues. They play key roles mediating cellular interactions with bioactive growth factors, cytokines, and morphogenetic proteins, and structural fibrillar collagens, cell interactive and extracellular matrix proteoglycans, and glycoproteins which define tissue function. Proteoglycan degradation detrimentally affects tissue functional properties. Therapeutic strategies have been developed to counter these degenerative changes. Neo‐proteoglycans prepared from chondroitin sulfate or hyaluronan and hyaluronan or collagen‐binding peptides emulate the interactive, water imbibing, weight bearing, and surface lubricative properties of native proteoglycans. Many neo‐proteoglycans outperform native proteoglycans in terms of water imbibition, matrix stabilization, and resistance to proteolytic degradation. The biospecificity of recombinant proteoglycans however, provides precise attachment to native target molecules. Visco‐supplements augmented with growth factors/therapeutic cells, hyaluronan, and lubricin (orthobiologicals) have the capacity to lubricate and protect cartilage, control inflammation, and promote cartilage repair and regeneration of early cartilage lesions and may represent a more effective therapeutic approach to the treatment of mild to moderate OA and deserve further study

    Long-term safety and efficacy of eculizumab in generalized myasthenia gravis

    Get PDF

    Eculizumab improves fatigue in refractory generalized myasthenia gravis

    Get PDF

    Consistent improvement with eculizumab across muscle groups in myasthenia gravis

    Get PDF

    Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

    Get PDF
    OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

    Finding Aid for William J. Micheels Personal Papers and Publications, 1926-2000

    No full text
    William J. Micheels served as President/Chancellor of Stout State College, Stout State University, and University of Wisconsin-Stout from 1961-1972. Excerpts from Fall 2000 Stout Outlook, front page: A native of Menomonie, Micheels was graduated from The Stout Institute in 1932, and earned a Master of Science degree in 1938 and a Doctor of Philosophy degree in 1941 at the University of Minnesota. For four years he was an instructor in industrial arts at the Shelby (Mont.) High School, and from 1936 to 1941, headed the industrial arts department at University High School in Minneapolis. During World War II, he had assignments at the Armored Force School at Fort Knox, Ky., and the Office of Defense Transportation in Washington D.C. From 1946 to 1961, he taught trade and industrial education at the University of Minnesota, becoming chair of the department of industrial education in 1954. He held a number of major international assignments. In 1949, he was visiting expert for training demonstration school staff in Germany for the U.S. Government, and in 1958-60 he served as a Ford Foundation Consultant to the Indonesian Ministry of Education. During his decade of leadership [at Stout, 1961-1972], Stout’s enrollment increased from 1,600 to 5,200. Fourteen undergraduate majors and five graduate majors were added to the curriculum, along with three new degrees including the education specialist degree. He was founder of the department of art and design. Micheels Hall, a major campus facility, was dedicated in his honor on Sept. 26, 1996. Micheels passed away May 31, 2000, at age 89 in Lake San Marcos, California.This collection includes correspondence, speeches, and publications from President Micheels
    corecore